gergel ivan   zoominfocom ivan p gergel sells  shares of nektar therapeutics nasdaqnktr stock notizie analysts opinions on american axle  manufacturing holdings inc axl brokerages set boohoocom plc lonboo price target at  energy changes will save consumers £bn in coming decades  government swedish govt leaks massive trove of citizens data kinder morgan kmi given media impact rating of  youtube tv is now live though only in five major american cities interocean capital llc buys  shares of cisco systems inc csco notizia affari cultura scienza sportivo internazionale salute nazionale affari cultura scienza sportivo internazionale salute nazionale ivan p gergel sells  shares of nektar therapeutics nasdaqnktr stock paterniano del favero luglio   condividere bank of montreal can now owns  shares of the biopharmaceutical companys stock worth  after buying an additional  shares during the period the price index m for nektar therapeutics nasdaqgsnktr is  hedge funds and other institutional investors own  of the companys stock state street corp boosted its position in shares of nektar therapeutics by  in the fourth quarter camber capital management llc increased its position in shares of nektar therapeutics by  in the fourth quarter municipal employees retirement system of mi boosted its position in nektar therapeutics by  in the first quarterreceive news  ratings for nektar therapeutics daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for nektar therapeutics and related companies with marketbeatcoms free daily email newsletter finally marshall wace north america lp bought a new position in shares of nektar therapeutics during the first quarter worth approximately shares of nektar therapeutics nasdaq nktr opened at  on friday the average volume stands around  million shares nektar therapeutics has a year low of  and a year high of  the consensus recommendation for stock is  state of alaska department of revenue now owns  shares of the biopharmaceutical companys stock worth  after buying an additional  shares in the last quarternektar therapeutics nasdaqnktr last announced its earnings results on tuesday may th the biopharmaceutical company reported  earnings per share for the quarter missing the consensus estimate of  by  nektar therapeutics had a negative net margin of  and a negative return on equity of  the company had revenue of  million during the quarter compared to the consensus estimate of  million equities research analysts anticipate that nektar therapeutics will post  earnings per share for the current fiscal year  brean capital began new coverage on nektar therapeutics giving the company a  rating equities research analysts expect that nektar therapeutics will post  eps for the current yearillegal activity warning this article was first published by sports perspectives and is the sole property of of sports perspectives if you are accessing this report on another domain it was copied illegally and reposted in violation of usa and worldwide trademark and copyright laws the original version of this piece of content can be read at httpstranscriptdailycomfranklinstreetadvisorsincnchasstakeinnektartherapeuticsnasdaqnktrupdatedhtmlseveral research analysts have weighed in on the stock jefferies group llc upped their price objective on shares of nektar therapeutics from  to  and gave the stock a positive rating in a research note on tuesday march st finally piper jaffray companies reiterated an overweight rating and issued a  price objective on shares of nektar therapeutics in a research note on tuesday april th bidaskclub raised nektar therapeutics from a hold rating to a buy rating in a report on tuesday june th valuengine raised shares of nektar therapeutics from a sell rating to a hold rating in a research note on friday june nd two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock the stock has a consensus rating of buy and an average price target of on july   nektar therapeutics a de corporation nektar entered into a license agreement the agreement with eli lilly and company an in corporation lillythe agreement is subject to review by the u s government under the hartscottrodino act the hsr act and will not become effective until the expiration or earlier termination of the waiting period or any extension thereofeither party may terminate the agreement  days after the date of filing under the hsr act if the transaction is not effective by that date the shares were sold at an average price of  for a total value of  following the completion of the transaction the chief executive officer now owns  shares in the company valued at approximately  the sale was disclosed in a legal filing with the securities  exchange commission which is available through the sec website also svp stephen k doberstein sold  shares of the companys stock in a transaction on tuesday may th following the transaction the senior vice president now directly owns  shares in the company valued at  the disclosure for this sale can be found here ls investment advisors llc now owns  shares of the biopharmaceutical companys stock valued at  after buying an additional  shares during the last quarternektar therapeutics is a biopharmaceutical companythe companys immunology pipeline is led by baricitinib an incyte codeveloped oncedaily oral rheumatoid arthritis drug approved in europe as olumiant but whose fda review ended in april with a complete response letter requesting additional clinical data altre relazioni overnewsmagazine  luglio  odonnell explains nascars laterace timing decisions at indy  luglio  fomento economico mexicano sab de cv green plains inc gpre shares bought by schwab charles investment management inc  luglio  meizu pro  al centro di un nuovo video leaked  luglio  simona ventura non sposa più gerò carraro novità con stefano bettarini intrepid potash inc nyseipi short interest up  in june  luglio  nolans dunkirk wins the weekend box office with m  luglio  belen e stefano pace social lei lo segue su instagram lui commenta  luglio  issue reslovedthe customer got the replacement xiaomi redmi note  de burlo group inc sells  shares of gilead sciences inc gild  luglio  worlds first floating wind farm emerges off coast of scotland  luglio  crash bandicoot n sane trilogy beats splatoon  in uk game charts recenti news articoli three new toad species discovered in us memorable moments from sean spicers tenure as press secretary shrinkflation has hit over  consumer products over the past five years discuti questo articolo più popolare overnewsmagazine harteau please support arradondo as new minneapolis police chief taliban take control of two districts in afghanistan microsofts secondgeneration hololens will include a dedicated ai coprocessor li haotong shoots  in final round of british open black lightning casts james remar  damon gupton as series regulars watch trailer temptation island  anticipazioni  luglio japans mitsubishi tanabe pharma to buy israeli company neuroderm for  billion heres how much christopher nolans dunkirk earned at the indian box office ongc deal arun jaitley panel to oversee divestment says dharmendra pradhan united kingdom government to regulate drones and assess drone users segui i nostri giornale ultime notizie overnewsmagazine analysts opinions on american axle  manufacturing holdings inc axl brokerages set boohoocom plc lonboo price target at  energy changes will save consumers £bn in coming decades  government swedish govt leaks massive trove of citizens data kinder morgan kmi given media impact rating of  ford juices up  mustang with optional drag strip mode norway takes lead in race to build autonomous cargo ships fidelity national financial inc macquarie reiterates buy rating for amazoncom inc nasdaqamzn neuroderm ltd ndrm coverage initiated at deutsche bank ag altre notizie scienza cultura affari about  shares traded facebook inc nasdaqfb has risen  the no  irving park and no  addison buses will also have extra  previously the company implemented a feature where the device would c capital management corp va now owns  shares of the financial serv the farreaching range of these deposits milliken says is crucial  there are just a few hours left of love island  and if you want  the movie is about the battle of dunkirk  where ordinary citizens to forse non tutti sanno che il gran maestro  personaggio che fa la sua my moneys on arya changing her mind and turning back toward kings  naturally the la la land actor was flattered by the pop stars admi public employees retirement system of oh boosted its position in amer centurylink inc nysectl has declined  since july   and  in a trading statement the energy storage technology company said the this network is connected to the european unions stesta which is a e zimmer partners lp sold m shares as kinder morgan inc del kmis    overnewsmagazinecom overnewsmagazine sportivo scienza cultura affari nazionale salute internazionale edizione contatti   ivan gergel  endo pharmaceuticals holdings inc  zoominfocom ivan p gergel md  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in ivan p gergel md senior vice president drug development and chief medical officer at nektar therapeutics view full profile are you ivan p gergel md claim your profile   sign up for equilar atlas and view ivan p gergel mds full profile with equilar atlas you can identify corporate executives in ivan p gergel mds network and community follow changes in ivan p gergel mds employment and moneyinmotion connect with ivan p gergel md through your network of contacts ivan p gergel mds executive work history current senior vice president drug development and chief medical officer nektar therapeutics board member corium international inc past to view ivan p gergel mds complete executive work history sign up now education md university of london age      ivan p gergel mds biography ivan p gergel md has served as our senior vice president drug development and chief medical officer since may  from april  through march  dr gergel served as executive vice president research  development and chief scientific officer of endo pharmaceuticals a pharmaceutical company prior to joining endo pharmaceuticals he was senior vice president of scientific affairs and president of the forest research institute of forest laboratories inc prior to that dr gergel served as vice president and chief medical officer at forest and executive vice president of the forest research institute he joined forest in  a  read more ivan p gergel md has served as our senior vice president drug development and chief medical officer since may  from april  through march  dr gergel served as executive vice president research  development and chief scientific officer of endo pharmaceuticals a pharmaceutical company prior to joining endo pharmaceuticals he was senior vice president of scientific affairs and president of the forest research institute of forest laboratories inc prior to that dr gergel served as vice president and chief medical officer at forest and executive vice president of the forest research institute he joined forest in  as executive director of clinical research following nine years at smithkline beecham and was named vice president of clinical development and clinical affairs in  dr gergel is a member of the board of directors of corium international inc a commercialstage biopharmaceutical company dr gergel received his md from the royal free medical school of the university of london and an mba from the wharton school source nektar therapeutics on    sign up for equilar atlas and view ivan p gergel mds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like ivan p gergel md more specifically youll be able to identify corporate executives in ivan p gergel mds network and community follow changes in ivan p gergel mds employment and moneyinmotion connect with ivan p gergel md through your network of conections view full profile   search for over  executive profiles bio example ivan p gergel md ivan p gergel mds connections  sign up now to view ivan p gergel mds  connections » gil m labrucherie senior vice president and chief financial officer nektar therapeutics roger h kimmel chairman of the board endo international plc william p montague former board member endo international plc maninder hora senior vice president pharmaceutical development and manufacturing operations nektar therapeutics dennis l winger board member accuray incorporated camille i farhat president chief executive officer and director rti surgical inc peter d staple dir president and chief executive officer corium international inc edward j sweeney former principal accounting officer endo international plc robert b chess chairman of the board nektar therapeutics john nicholson senior vice president and chief operating officer nektar therapeutics popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla daniel a dematteo executive chairman gamestop corp david j oconnor president and ceo the madison square garden company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax     forbidden access is denied server error   forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied ivan p gergel  malvern pa  intelius sign in we found ivan p gergel in malvern pa ivan p gergel intelius found that ivan p gergel is a male between  and  years old from malvern pa we have connected them to  addresses  phones and  relatives or associates also known as ivan highley gergel get report now age ivan p gergel is in his s ivan has lived in malvern pa berwyn pa armonk ny ivans relatives ann gergel highley ann peter ond ivan p gergel zodiac signaries gendermale professional status senior vice president drug development and chief medical officer at nektar therapeutics get report now want to know more about ivan get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about ivan or use our people search engine to find others get background check on ivan p gergel get a criminal check on ivan p gergel get a public record report on ivan p gergel get a people search report on ivan p gergel ivan p gergels contact information known cities lived in find out where ivan p gergel has lived as well as ivan p gergels phone numbers and email addresses ivan p gergel has lived in  states pennsylvania address for ivan p gergel  l b r malvern pa has lived in malvern pa berwyn pa get full address report phone numbers associated with ivan p gergel    malvern pa    washington dc    chadds ford pa get full phone report email addresses associated with ivan p gergel gncom ilcom gicom get email report ivan p gergels professional information information regarding ivan p gergels professional history find out previous places ivan p gergel has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act ivan p gergel has worked at  places company nektar therapeutics title senior vice president drug development and chief medical officer company endo pharmaceuticals title executive vice president  research  development chief scientific officer endo pharmaceuticals ivan p gergels experience title senior vice president drug development and chief medical officer company nektar therapeutics job details company size  mil to less than  mil  employee range  to less than  title executive vice president  research  development chief scientific officer endo pharmaceuticals company endo pharmaceuticals job details company size  bil and above  employee range  to less than  additional professional information on ivan p gergel see ivan p gergels linkedin profile ivan p gergels social network and potential email matches find out potential social network profiles and potential email usernamed for ivan p gergel ivan p gergels known social networks and potential email matches find all of ivan p gergels social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches ivan gergel username matches ivangergel gergelivan ivangergel gergelivan ivangergel gergelivan ivangergel gergelivan igergel popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches i gergel intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here ﻿ ivan p gergel sells  shares of nektar therapeutics nasdaqnktr stock  stocknewstimes daily ratings  news for nektar therapeutics complete the form below to receive the latest headlines and analysts recommendationsfor nektar therapeutics with our free daily email newsletter follow stocknewtimes recent posts brokerages expect hewlett packard enterprise company hpe will post earnings of  per share hewlett packard enterprise company hpe expected to announce quarterly sales of  billion zacks brokerages expect aduro biotech inc adro to announce  eps ryerson holding corporation ryi expected to post earnings of  per share athenahealth inc nasdaqathn rating increased to b at thestreet  eps expected for leap therapeutics inc nasdaqlptx this quarter eqt midstream partners lp nyseeqm upgraded to “b” at thestreet philip morris international inc nysepm rating increased to b at thestreet first solar inc nasdaqfslr upgraded by thestreet to “c” athenahealth inc nasdaqathn upgraded by thestreet to b wayfair w vs amazoncom amzn financial comparison companhia de saneamento basico do estado de sao paulo – sabesp sbs versus california water service group holding cwt headtohead comparison magna international mga  tenneco nyseten head to head analysis contrasting treehouse foods ths and jm smucker company the sjm critical survey ah belo corporation ahc and lee enterprises nyselee ally financial inc nyseally upgraded to b by thestreet polaris industries inc pii upgraded at thestreet  million in sales expected for summit therapeutics plc nasdaqsmmt this quarter rayonier inc ryn receives  average target price from brokerages zacks analysts expect cellectis sa clls to announce  eps ivan p gergel sells  shares of nektar therapeutics nasdaqnktr stock posted by mandy boone on jul rd   no comments nektar therapeutics nasdaqnktr svp ivan p gergel sold  shares of the business’s stock in a transaction dated tuesday july th the stock was sold at an average price of  for a total transaction of  following the completion of the sale the senior vice president now owns  shares in the company valued at  the transaction was disclosed in a legal filing with the sec which can be accessed through this hyperlink nektar therapeutics nktr opened at  on friday the company’s  day moving average is  and its day moving average is  nektar therapeutics has a year low of  and a year high of  the stock’s market capitalization is  billion get nektar therapeutics alerts nektar therapeutics nasdaqnktr last released its quarterly earnings data on tuesday may th the biopharmaceutical company reported  earnings per share eps for the quarter missing the thomson reuters’ consensus estimate of  by  nektar therapeutics had a negative return on equity of  and a negative net margin of  the firm had revenue of  million for the quarter compared to analyst estimates of  million during the same quarter in the previous year the business posted  earnings per share nektar therapeutics’s revenue for the quarter was down  on a yearoveryear basis analysts forecast that nektar therapeutics will post  earnings per share for the current fiscal year illegal activity warning this report was first posted by stocknewstimes and is the property of of stocknewstimes if you are accessing this report on another domain it was copied illegally and reposted in violation of us and international trademark and copyright laws the legal version of this report can be accessed at httpsstocknewstimescomivanpgergelsellssharesofnektartherapeuticsnasdaqnktrstockhtml a number of large investors have recently added to or reduced their stakes in nktr rothschild capital partners llc purchased a new stake in nektar therapeutics during the second quarter valued at about  harvey capital management inc boosted its stake in nektar therapeutics by  in the second quarter harvey capital management inc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the last quarter aperio group llc boosted its stake in nektar therapeutics by  in the second quarter aperio group llc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the last quarter louisiana state employees retirement system boosted its stake in nektar therapeutics by  in the second quarter louisiana state employees retirement system now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the last quarter finally ls investment advisors llc boosted its stake in nektar therapeutics by  in the second quarter ls investment advisors llc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the last quarter hedge funds and other institutional investors own  of the company’s stock nktr has been the topic of a number of research reports zacks investment research upgraded shares of nektar therapeutics from a “sell” rating to a “hold” rating in a report on monday march th aegis boosted their target price on shares of nektar therapeutics from  to  and gave the stock a “buy” rating in a report on thursday april th piper jaffray companies restated an “overweight” rating and issued a  target price on shares of nektar therapeutics in a report on tuesday april th jefferies group llc set a  target price on shares of nektar therapeutics and gave the stock a “buy” rating in a report on saturday april nd finally roth capital set a  target price on shares of nektar therapeutics and gave the stock a “buy” rating in a report on thursday may th two analysts have rated the stock with a hold rating and nine have given a buy rating to the company the stock presently has an average rating of “buy” and a consensus price target of  nektar therapeutics company profile nektar therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need the company’s research and development pipeline of new investigational drugs includes treatments for cancer autoimmune disease and chronic pain it leverages its chemistry platform to discover and design new drug candidates receive news  ratings for nektar therapeutics daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for nektar therapeutics and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website page not found  leadership directories products blogs about client support order return home     contact us toll free   broadway suite  new york ny  tel       fax    k street nw suite  washington dc  tel         fax   terms of use  privacy policy  faq  contact us  leadership directories inc